化学品的无动物安全评估:一个创新系统的前景
Marjolein J Hoogstraaten1,2, Jelle Vriend3, Victoria C de Leeuw3
1Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands. M.J.Hoogstraaten@VU.nl.
Archives of toxicology
|October 4, 2024
概括
本文介绍了一个框架,用于评估使用新方法方法 (NAMs) 进行无动物化学安全测试的进展. 它强调了超越科学的系统变革的必要性,以确保NAM的接受和普及.
科学领域:
- 毒理学和化学安全评估
- 创新与转型研究 研究创新与转型研究
背景情况:
- 无动物化学品安全评估的科学和技术挑战是众所周知的.
- 任务和路线图加快了新方法方法论 (NAM) 的接受和使用.
- 系统性的社会,机构和监管转变对于NAM采用至关重要.
研究的目的:
- 为理解和评估在无动物化学品安全评估中的任务成就提供一个启发式框架.
- 利用创新系统文献来掌握NAM过渡所需的系统变化.
- 识别技术领域以外的关键流程和活动,以加快NAM接受.
主要方法:
- 利用创新系统文献来开发一个启发式框架.
- 分析过渡到无动物安全评估的系统要求.
- 确定促进NAM接受和普及的关键过程和活动.
主要成果:
- 创新系统方法为超越技术和科学的过程提供了洞察力.
- 提出了一个全面的框架,将科学/技术发展与教育,培训,资金,政策和公众参与相结合.
- 该框架促进了NAM创新系统的结构和功能分析.
结论:
- 为了成功过渡到无动物化学品安全评估,必须采取协调,多方面的方法.
- 拟议的框架有助于跟踪进展并组织为采用NAM采取集体努力.
- 超越技术进步需要解决更广泛的社会和监管因素,以有效实施NAM.
相关概念视频
Effects of Chemicals: Overview
2.4K
Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
2.4K
Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Toxicity Testing in Animals
200
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
200
Production of Biopesticides
99
Biopesticides offer a sustainable alternative to chemical pesticides, utilizing microbial agents to control agricultural pests. Bacillus thuringiensis (Bt) is a widely employed bacterium known for its potent insecticidal activity. Bt biopesticides are favored for their specificity to insect pests, minimal environmental impact, and natural degradability.Mechanism of Bt Toxin Action Bt produces insecticidal crystal (Cry) proteins during its sporulation phase. These proteins form parasporal...
99


